Evaluation of platelet-rich plasma efficacy in melasma

Basit Öğe Kaydı
dc.authoridUnal, Idil/0000-0002-1639-277X
dc.authoridAcar, Ayda/0000-0001-7507-6999
dc.authorscopusid56417418700
dc.authorscopusid57803376800
dc.authorscopusid57208322145
dc.authorscopusid6602966718
dc.authorscopusid57211443745
dc.contributor.authorAcar, Ayda
dc.contributor.authorOzturk, Ayris
dc.contributor.authorSokmen, Nur
dc.contributor.authorUnal, Idil
dc.contributor.authorSagduyu, Ilgen Ertam
dc.date.accessioned2023-01-12T19:59:50Z
dc.date.available2023-01-12T19:59:50Z
dc.date.issued2022
dc.departmentN/A/Departmenten_US
dc.description.abstractPlatelet-rich plasma (PRP), which is widely used in many dermatologic conditions, has also been used in the treatment of melasma in recent years. The objective of this study is to determine the efficacy of PRP in melasma. Fifteen female patients with melasma participated in this study. Intradermal PRP was performed every 3 weeks for three times. We photographed all participants, performed Melasma Area and Severity Index (MASI), and measured melanin and erythema index (EI) with mexameter before every session and 1 month after the last session. Patients self-assessment of pigmentation grade (0-10) were also employed at baseline and 1 month after the last procedure. Mean MASI of the patients reduced from 10 +/- 3.6 to 7.3 +/- 2.5. Melanin index (MI) and EI evaluated by mexameter reduced from 256.5 +/- 31 to 238.9 +/- 29.9 and from 329.9 +/- 53.8 to 322.7 +/- 77.6, respectively. Mean patients self-assessment score (PSS) reduced from 8.3 +/- 1.3 to 5 +/- 1.4. Mean MASI, MI, and PSS reduction after treatment was found significant (p = .001, p = .000, p = .000). Intradermal application of PRP is an effective option for treatment of melasma. It also has other benefits like improvement in skin appearance. Because recurrence is common in melasma, depigmenting agents should be used after all procedures.en_US
dc.description.sponsorshipEge University Scientific Research Projects Coordination Unit [TGA-2020-21941]en_US
dc.description.sponsorshipThis study is supported by Ege University Scientific Research Projects Coordination Unit. Project Number: [TGA-2020-21941].en_US
dc.identifier.doi10.1080/14764172.2022.2099898
dc.identifier.endpage39en_US
dc.identifier.issn1476-4172
dc.identifier.issn1476-4180
dc.identifier.issue1-5en_US
dc.identifier.pmid35852165en_US
dc.identifier.scopus2-s2.0-85134241557en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage36en_US
dc.identifier.urihttps://doi.org/10.1080/14764172.2022.2099898
dc.identifier.urihttps://hdl.handle.net/11454/77242
dc.identifier.volume24en_US
dc.identifier.wosWOS:000827563700001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Incen_US
dc.relation.ispartofJournal of Cosmetic and Laser Therapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectmelasmaen_US
dc.subjectMelasma Area and Severity Indexen_US
dc.subjectmexameteren_US
dc.subjectplatelet-rich plasmaen_US
dc.titleEvaluation of platelet-rich plasma efficacy in melasmaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu